The Global TB CAB and TAG commend the investigators for sharing results early and openly with a diverse group of key stakeholders, and urge the scientific community and funders to continue efforts to find different options to prevent TB.

Historic price reductions will allow millions more people to receive TB prevention, treatment and testing.

Two position papers, developed by the Global TB Community Advisory Board (TB CAB), are published in the September 2023 issue of Public Health Action.

Statement by Treatment Action Group (TAG) and the Global Tuberculosis Community Advisory Board (TB CAB)

Advocates demand that the Indian government take urgent action to ensure that every eligible person with TB has access to evidence-based, short-course treatment regimens.

Advocates urge the Indian government to issue compulsory licenses for patents on bedaquiline and delamanid to make the drugs more affordable and accessible.

Deadline for applications: 19 February 2021

TB CAB Access Considerations Statement Regarding Johnson & Johnson Announcement of Bedaquiline Price Reduction

Advocates request an urgent in-person meeting with the WHO leadership to discuss concrete actions to address technical and guideline development process-related issues previously raised.

TB CAB releases document outlining key considerations regarding pretomanid in anticipation of FDA public advisory committee meeting on the TB Alliance's new drug application for pretomanid.